Outpatient Versus Inpatient Care Pathway for Intra-arterial Treatment of Primary Liver Cancer (CHOC)

Prior treatment

• Patient previously included in the study
• Concomitant disease or severe uncontrolled clinical situation

Other illness

• Chronic renal insufficiency (Clairance \< 30 ml/min)
• Known allergy to a contrast agent or chemotherapy agent
• Severe uncontrolled infection
• Person under compulsory psychiatric care

Other

• Technical contraindication or morphological elements of predictable technical difficulty
• Planned combined same-day therapeutic strategies at the index procedure (e.g., TACE combined with percutaneous ablation) are not allowed; sequential (non-same-day) treatments are allowed.
• inability to participate in ambulatory care (inability to understand and follow discharge instructions, lack of reliable telephone access, absence of a responsible accompanying adult for the first night after discharge, or inability to access urgent care in a timely manner if symptoms occur)
• Patient who, for psychological, social, family or geographical reasons, could not be regularly monitored, patient who, for psychological, social, family or geographical reasons, could not be followed regularly
• Pregnant, breast-feeding or parturient woman
• Person deprived of liberty by judicial or administrative decision
• Person under a legal protection measure
• Person unable to give consent

• Age ≥ 18 years
• HCC or iCCA diagnosed according to the criteria of the European Association for the Study of the Liver (2024) or histologically proven.
• Patient with HCC or iCCA eligible for intra-arterial treatment (transarterial chemoembolization \[TACE\] or transarterial radioembolization \[TARE\]), with no prior intra-arterial treatment of the same type as the one planned in the trial:
  • no prior TACE for patients included for TACE;
  • no prior TARE for patients included for TARE. Prior intra-arterial treatment of the other type is allowed (prior TACE before TARE, or prior TARE before TACE). Prior non-intra-arterial treatments are allowed.
• If TACE is proposed at the multidisciplinary tumour board (RCP):
  • Patient Child-Pugh \< B8
  • Single or multiple HCC
  • Absence of lobar or truncal portal obstruction
  • Absence of bile duct dilatation
• If treatment by TARE proposed in RCP:
  • Absence of truncal portal tumor invasion
  • Uni-lobar tumor invasion (except for centrohepatic iCCA)
  • Total bilirubin \< 20 mg/l (or 35 µmol/L)
• Patient affiliated to or benefiting from a social security scheme
• Patient having signed an informed consent form